Purolite and Codexis Announce Collaboration to Develop and Market Immobilized Enzymes for Pharmaceutical Market

  Purolite and Codexis Announce Collaboration to Develop and Market
  Immobilized Enzymes for Pharmaceutical Market

Business Wire

BALA CYNWYD, Pa. & REDWOOD CITY, Calif. -- July 15, 2013

Purolite Corporation and Codexis, Inc. (NASDAQ:CDXS) today announced a joint
collaboration to develop and market immobilized enzymes for the pharmaceutical

Enzymes are immobilized through binding to inert resins, allowing for easier
separation from a reaction mixture, and immobilization often allows for the
use of these enzymes under different conditions and re-use at a commercial
scale. The collaboration will enable Purolite and Codexis to develop
immobilized transaminase enzymes for use in the production of pharmaceuticals.

“We have selected Purolite as a partner for immobilization based on their
experience with support resins and their ability to supply those resins at
every scale,” said Dr. Peter Seufer-Wasserthal, Senior Vice President,
Pharmaceuticals at Codexis. “Under this new collaboration with Purolite, we
will be launching a kit of immobilized transaminases as an extension of our
CODEX® Screening Kits. The new immobilized enzyme kits will allow potential
customers to quickly assess ideas for biocatalytic processes.”

“We are very proud to partner with Codexis,” said Dr. Alessandra Basso,
Business Manager of the LifeTech™ unit at Purolite. “The successful
implementation of these ready-to-use immobilized enzymes for fast screening
processes opens the door to new concepts of drug development, where scientists
who are unfamiliar with biocatalytic processes can easily apply immobilized
enzymes to different screening processes that can speed up new-molecule and
API development.”

About Purolite

Purolite was founded in 1981 and is a leading manufacturer of ion exchange,
catalyst, adsorbent and specialty resins.They have developed the widest
platform of resins for enzyme immobilization as part of the LifeTech product
portfolio. Headquartered in Bala Cynwyd, Pa., the company has ISO-certified
manufacturing facilities in the USA, China, and Romania and operates dedicated
R&D centers in the USA, China, Romania, Russia, and the UK. Purolite, the only
company focused exclusively on the ion exchange market, has 40 sales offices
in more than 30 countries. For more information, see www.purolite.com.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and implementation of
biocatalytic solutions to meet customer needs for rapid, cost-effective and
sustainable process development – from research to manufacturing. For more
information, see www.codexis.com.

Codexis Forward-Looking Statements

This press release contains forward-looking statements relating to potential
launch of immobilized enzyme kits. You should not place undue reliance on
these forward-looking statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond our control
and could materially affect actual results. Factors that could materially
affect actual results include our dependence on a limited number of products
in our pharmaceutical business; potential adverse affects to our business if
our customers’ pharmaceutical products are not received well in the markets;
and our ability to develop and commercialize new products for the
pharmaceutical market. Additional factors that could materially affect actual
results can be found in Codexis’ Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May 9, 2013, including under the caption
“Risk Factors.” Codexis expressly disclaims any intent or obligation to update
these forward-looking statements, except as required by law.


Codexis, Inc.
Paul Cox, 212-362-1200
Jemma Connor, +44 161 359 3255
Jacob Brodie, Vice President, 267-255-4829
Press spacebar to pause and continue. Press esc to stop.